Dr. Makoto Nakamura graduated from the department of medicine, Kobe University in 1986. He developed his clinical skills in Kanazawa University and worked as a clinical pediatrician for 10 years.
His specialty is pediatric cardiology. After receiving the Ph.D. degree (Medicine) from Kanazawa University, he started the research on artificial heart from 1996 in National Cardiovascular Center Japan. In 1999, he was appointed as associate professor of Tokyo Medical and Dental University. During these research experiences, he learned several limitations of mechanical artificial organs, and he started the researches on tissue engineering. He focused on applying printing technology into tissue engineering, which is now called bioprinting and biofabrication. And he developed an inkjet 3D-bioprinter in 2006. In 2008, he became a professor of University of Toyama.
He has contributed much to developing bioprinting and biofabrication and to the establishment of the international society for biofabrication (ISBF) in 2010 as an inaugural board member. He organized the 2nd. annual conference of ISBF 2011 in Japan
Chief Scientific Officer for Rare Diseases at Moderna
Paolo Martini is the Chief Scientific Officer for Rare Diseases at Moderna. With more than 20 years of experience in drug discovery working on molecular mechanisms underlying monogenic and multigenic metabolic and fibrotic disorders as well as hematologic malignancies, his laboratory is focused on identifying novel therapies and applying translational approaches for drug development in Rare Diseases. Currently exploring the identification of several targets and key animal models for translating messenger RNA therapeutic in human patients with rare genetic disorders.
Previously at Shire Pharmaceutical in Lexington, MA, as Senior Director of Discovery Biology and Translational Research, Massachusetts, his focus was on fibrotic diseases of muscle, kidney, skin, lung, bone marrow and metabolic liver diseases with particular emphasis on different therapeutic modalities for pathway modulation. He has been supporting phase 1 and 2 clinical studies for lysosomal storage and chronic kidney diseases.
He has also worked at EMD-Serono prior to Shire in Discovery Research. After graduating at the University of Milan, Italy, he moved to Germany for a post-doctoral work at Schering AG (now Bayer) in Berlin, Germany, and then to the University of Illinois in Urbana Champaign (USA). He has been collaborating with organizations supporting research and clinical development of rare metabolic disorders and fibrotic diseases and he is currently a member of the Scientific Advisory Board of the Keystone Symposia.
Head of King Abdullah International Medical Research Center Jeddah (KAIMRC-J)
Dr. Suliman Al Ghamdi joined King Abdulaziz Medical City, Western Region in August 2005 as Associate Consultant, Department of Oncology, and promoted to Consultant position in 2007 and was appointed as Section Head, Radiation Oncology in August 2007. In August 2010, he was appointed as Deputy Chairman, Princess Nourah Oncology Center, King Abdulaziz Medical City, Western Region. In August 2011, he was appointed as Deputy Head, King Abdullah International Medical Research Center, Western Region. In August 13, 2013, Dr. Ghamdi was appointed as the Head of King Abdullah International Medical Research Center – Western Region and up to now is still the head of the Research Center in Jeddah.
Dr. Suliman Al Ghamdi graduated from King Abdulaziz University, Faculty of Medicine, Jeddah, Saudi Arabia in 1997, and completed his internship in the same institution in 1998. He completed his Residency Training Program in Radiation Oncology from January 2000 till December 2004 at Ottawa Regional Cancer Centre, University of Ottawa, Ontario, Canada, followed by fellowship training in Radiation Oncology with sub – specialization in Stereotactic Radiosurgery of Head and Neck, CNS Malignancies and Brachytherapy in 2005. He also obtained FRCPC certificate on May 28, 2004.
Advisor to the Minister for Pharmaceutical Sector Development
Advisor to the Minister for Pharmaceutical Sector Development
Ibrahim Aljuffali is the Executive Vice President for Drug Sector at Saudi FDA. Dr. Aljuffali earned his PhD degree in Pharmaceutical sciences from the University of Georgia (UGA) with research emphasis in Nontechnology and Pharmacokinetics/Pharmacodynamics. Dr. Aljuffali also earned a Master of Science Degree in Pharmacy with an emphasis in Regulatory Affairs and graduate diploma in Clinical Trials Design & Management from University of Georgia.
Dr. Aljuffali Also serve as an Associate Professor at King Saud University. He chairs and patriate in different local and national committee related to health and drug regulation.
Eng. Nizar Al-Hariri comes with over 23 years’ of successful track record of business development in both government and private sectors. Experienced across all aspects of business developments from concept to JV set-ups, contractual negotiations and funding arrangements to major project management, strategic planning and organization structuring. He has proven ability in developing business strategies and plans based on exceptional analytical skills, achieving business goals and taking full P&L responsibility. Having worked in SIDF for ten years and managed Capital Advisory Group for five, he has a recognized management and consultancy records appointed him to manage the advisory services for the Economic Offset Program, EOP and Public Investment Fund, PIF between 2003 and 2006. Later, Eng. Al-Hariri was assigned as CEO for CAD Middle East for Pharmaceutical Industries. He was responsible for introducing a ground breaking concept of building the first GMP state-of-the-art Active Pharmaceutical Ingredients (API) facility in Saudi Arabia and the MENA region.
Eng. Nizar Al-Hariri has a BSc in Chemical Engineering from King Saud University, and post graduate from the University of Cambridge, Engineering Dept. in Design, Manufacture & Management – ACDMM
Director , Medical Biotechnology Park Head, Strategy and Business Development, KAIMRC. MNG-HA
Director , Medical Biotechnology Park
Head, Strategy and Business Development, KAIMRC. MNG-HA
Dr. Haoudi is currently leading the R&D Strategy and Business Development at King Abdullah International Medical Research Center at the Ministry of National Guard Health Affairs and is also Visiting Scientist at Boston Children’s Hospital-Harvard Medical School.
Dr. Haoudi held several senior R&D positions in the academia, government and private sectors including Executive Director for R&D, Founding Vice President for Research at Qatar Foundation and Chairman of Exceptional National Priorities Grants Programs. Dr. Haoudi was also Research Professor of cancer and infectious diseases and a fellow of the US National Institutes of Health. He has also held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institut Pasteur (France) and had served as consultant and advisor to several biotechnology and pharmaceutical companies.
Dr. Haoudi was elected as a member of the Royal Academy for Science and Technology since 2006 and graduated from University Paris XI, France in 1996 with a doctoral degree in cellular and molecular genetics and received executive education from Harvard Business School in Corporate management and strategy. Dr. Haoudi has also founded and served as the Editor-in-Chief for the Journal of Biomedicine and Biotechnology over 8 years.
He led the process of establishing the pharmaceutical products evaluation directorate at SFDA, which is the scientific backbone of the drug sector since 2009. Dr. Almazroo was the first director appointed for pharmaceutical products evaluation. With his colleagues, he developed many of the current scientific practices in the directorate. He also initiated, coordinated and conducted two clinical studies at the University of Pittsburgh Medical Center (UPMC), one of which was Phase I/II – Investigational New Drug (IND) clinical study.
Dr. Almazroo graduated from School of Pharmacy, King Saud University with a Bachelor degree in Pharmaceutical Sciences. In 2009, he was among the top 10% of all graduates in the Master of Sciences in biopharmaceuticals from School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. On 27 April 2013, he was one of the first Saudi pharmacists to complete the Certificate in Clinical and Translational Sciences (master degree level) from the School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. In 2017, he received his PhD in Pharmaceutical Sciences from University of Pittsburgh. The PhD research was focused on hepatic ischemia and reperfusion injury in liver transplantation. He conducted preclinical and clinical studies, while his research involved in using ex-vivo, in-vivo and simulation models for pharmacokinetics, developed several mass spectrometry assays and utilized PCR techniques for gene characterization.
Executive Director, Infection Prevention and Control at the Ministry of National Guard
Dr. Hanan Balkhy is a graduate of King Abdulaziz University in Jeddah, Kingdom of Saudi Arabia. She completed her pediatric residency at Massachusetts General Hospital in Boston USA 1993-1996; followed by a pediatric infectious diseases fellowship training from 1996-1999 from a joint program of the Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, Ohio. Dr. Balkhy is American Board certified in both Pediatrics and Pediatric Infectious Disease.
Dr. Balkhy is currently the Executive Director, Infection Prevention and Control at the Ministry of National Guard, a corporate department that over sees the infection control functions of five hospitals under the umbrella of the Saudi Ministry of National Guard. She is also the Director of the GCC Center for Infection Control (2005-current) and the WHO CC (2009-current). The impact of these centers has been to enhance and unify practices in the healthcare settings to the best possible standard to ensure patient safety.
Dr. Balkhy is also an Associate Professor of King Saud bin Abdulaziz University for Health Science. Teaching and mentoring both medical and nursing students as well as supervising local and international postgraduate students. She is the Editor-in-Chief of the Journal of Infection and Public Health and has over 90 publications in peer reviewed journals. She has also been involved in the organization of many educational symposia and seminars in the field of infection control over the past 16 years, nationally and internationally, including ESCMID, ICPIC, ID Week and others. Dr. Balkhy is also on several WHO committees including the AGISAR, STAG-AMR, and the IHR RC. Finally she has recently been appointed the Chairman of the Infectious Disease Unit at King Abdullah International Medical Research Center at KAMC which focusses on relevant infectious disease research for emerging public health concerns such as multidrug resistance pathogens, hospital infections, tuberculosis and others and has received a research award from her institution acknowledging her leading role in her field. Dr. Balkhy has served on the External Affairs Committee for SHEA and has been recently elected on the board of trustees for SHEA as the international councilor.
Head Genetics Division, Department of Pediatrics , Associate Professor, King Saud bin Abdulaziz University for Health Sciences , MNG-HA
Dr. Majid Alfadhel is a Genetic and Pediatric Consultant at National Guard Health Affairs. Additionally, Dr. Alfadhel has been an associate professor at King Saud bin Abdulaziz University for the past five years. Alfadhel’s impressive educational background includes a Master’s degree in Epidemiology from the University of British Columbia, as well as fellowships in Neurometabolics and Biochemical Genetics.
Head, Developmental Medicine Department (DMD), KAIMRC
During Dr. Manal Alaamery’s work and career, she established herself as a research leader, received numerous awards, and published in prestigious peer-reviewed scientific journals. Dr. Alaamery also taught several courses, led many initiatives and held several committee positions. Her long-term goal as a scientist is to use her background and expertise in science to contribute to the medical field and develop programs and strategies that could improve research and medicine in the Kingdom of Saudi Arabia. She hope through her work to bridge the gap between research and clinical medicine, translating novel discoveries into clinical tests by using cutting-edge tests. She is currently the Head of Developmental Medicine Department (DMD) at King Abdullah International Medical Research Center (KAIMRC).
In addition, an active research scientist at KAIMRC. Formerly, Dr. Alaamery was an instructor at the Harvard Medical School/ Children’s Hospital Boston. She received her clinical and postgraduate training at Harvard Medical School Genetics Program. Her clinical training at the Laboratory of Molecular Medicine (LMM) at Harvard focused on the areas of Hypertrophic and Dilated Cardiomyopathies, Neurological disorders, Muscular disorders, Hearing loss, Noonan spectrum, Connective tissue disorders, Pharmacogenetics and Cancer genetics. Dr. Alaamery also hold a Doctoral (Ph.D.) degree in Molecular Genetics/Biology from Boston College and a Master of Science degree in Clinical Microbiology from Thomas Jefferson University. In addition, Dr. Alaamery is the Chairman of the Saudi Genome Project satellite KACST-NGHA lab, the principal investigator of the KAIMRC-KACST therapy development joint program, and the co-principal investigator of the genetic track of the Biomedicine Center of Excellence BWH-Harvard affiliated hospital-KACST.